Baidu
map

Indoor Air:对长途汽车工作人员进行过敏性鼻炎风险预测的诺模图构建

2020-06-09 AlexYang MedSci原创

最近,有研究人员调查了室内空气污染物和对过敏性鼻炎健康的影响情况。

最近,有研究人员调查了室内空气污染物和对过敏性鼻炎健康的影响情况。

研究包括了226个汽车站的3194名工作人员,并建立了诺模图模型来预测这些工作人员过敏性鼻炎的风险。研究人员测量了室内温度、相对湿度、PM10、PM2.5、总细菌量和总真菌量,并使用调查问卷收集了汽车站信息和工作人员健康信息。结果发现,PM10、PM2.5、总细菌和总真菌超标率分别为18.16%、31.13%、2.22%和55.89%。温度、相对湿度和PM2.5随着季节的变化而变化。客流量能够影响温度和总细菌。中央空调也能够影响总细菌。其中,15.9%的工作人员诊断为过敏性鼻炎。相对湿度、真菌、自我报告的过敏性鼻炎症状和吸烟是过敏性鼻炎的影响因素。这4个变量均整合进了诺模图中。训练集和测试集中诺模图的一致性为0.775(95% CI: 0.745-0.806)和0.749(95% CI: 0.715-0.783)。校准图表明诺模图模型具有很好的辨别力和一致性。

最后,研究人员指出,他们的模型能够帮助预测过敏性鼻炎的发生。

原始出处:

Li Li , Hang Liu , Yu Wang et al. Construction of a Nomogram for Predicting the Risk of Allergic Rhinitis Among Employees of Long-Distance Bus Stations in China. Indoor Air. 23 May 2019.

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2047266, encodeId=4c61204e2666b, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Fri Jun 19 21:22:36 CST 2020, time=2020-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=812034, encodeId=9d3f81203469, content=受教了, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/14/8d72952b2c7c88891566fd24b0601585.jpg, createdBy=21712106382, createdName=1861f7af3bm, createdTime=Sat Aug 22 14:43:04 CST 2020, time=2020-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463983, encodeId=f3de146398328, content=<a href='/topic/show?id=e58691932b6' target=_blank style='color:#2F92EE;'>#诺模图#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91932, encryptionId=e58691932b6, topicName=诺模图)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13c36558142, createdName=zhangyxzsh, createdTime=Thu Jun 11 04:22:36 CST 2020, time=2020-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469166, encodeId=cbca146916681, content=<a href='/topic/show?id=211f98250b' target=_blank style='color:#2F92EE;'>#IND#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9825, encryptionId=211f98250b, topicName=IND)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=16377007930, createdName=xiaogang319, createdTime=Thu Jun 11 04:22:36 CST 2020, time=2020-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485978, encodeId=994a14859e87c, content=<a href='/topic/show?id=2c62100911a3' target=_blank style='color:#2F92EE;'>#风险预测#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100911, encryptionId=2c62100911a3, topicName=风险预测)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e31a8064712, createdName=12498ebem21暂无昵称, createdTime=Thu Jun 11 04:22:36 CST 2020, time=2020-06-11, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2047266, encodeId=4c61204e2666b, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Fri Jun 19 21:22:36 CST 2020, time=2020-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=812034, encodeId=9d3f81203469, content=受教了, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/14/8d72952b2c7c88891566fd24b0601585.jpg, createdBy=21712106382, createdName=1861f7af3bm, createdTime=Sat Aug 22 14:43:04 CST 2020, time=2020-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463983, encodeId=f3de146398328, content=<a href='/topic/show?id=e58691932b6' target=_blank style='color:#2F92EE;'>#诺模图#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91932, encryptionId=e58691932b6, topicName=诺模图)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13c36558142, createdName=zhangyxzsh, createdTime=Thu Jun 11 04:22:36 CST 2020, time=2020-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469166, encodeId=cbca146916681, content=<a href='/topic/show?id=211f98250b' target=_blank style='color:#2F92EE;'>#IND#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9825, encryptionId=211f98250b, topicName=IND)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=16377007930, createdName=xiaogang319, createdTime=Thu Jun 11 04:22:36 CST 2020, time=2020-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485978, encodeId=994a14859e87c, content=<a href='/topic/show?id=2c62100911a3' target=_blank style='color:#2F92EE;'>#风险预测#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100911, encryptionId=2c62100911a3, topicName=风险预测)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e31a8064712, createdName=12498ebem21暂无昵称, createdTime=Thu Jun 11 04:22:36 CST 2020, time=2020-06-11, status=1, ipAttribution=)]
    2020-08-22 1861f7af3bm

    受教了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2047266, encodeId=4c61204e2666b, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Fri Jun 19 21:22:36 CST 2020, time=2020-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=812034, encodeId=9d3f81203469, content=受教了, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/14/8d72952b2c7c88891566fd24b0601585.jpg, createdBy=21712106382, createdName=1861f7af3bm, createdTime=Sat Aug 22 14:43:04 CST 2020, time=2020-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463983, encodeId=f3de146398328, content=<a href='/topic/show?id=e58691932b6' target=_blank style='color:#2F92EE;'>#诺模图#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91932, encryptionId=e58691932b6, topicName=诺模图)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13c36558142, createdName=zhangyxzsh, createdTime=Thu Jun 11 04:22:36 CST 2020, time=2020-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469166, encodeId=cbca146916681, content=<a href='/topic/show?id=211f98250b' target=_blank style='color:#2F92EE;'>#IND#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9825, encryptionId=211f98250b, topicName=IND)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=16377007930, createdName=xiaogang319, createdTime=Thu Jun 11 04:22:36 CST 2020, time=2020-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485978, encodeId=994a14859e87c, content=<a href='/topic/show?id=2c62100911a3' target=_blank style='color:#2F92EE;'>#风险预测#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100911, encryptionId=2c62100911a3, topicName=风险预测)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e31a8064712, createdName=12498ebem21暂无昵称, createdTime=Thu Jun 11 04:22:36 CST 2020, time=2020-06-11, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2047266, encodeId=4c61204e2666b, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Fri Jun 19 21:22:36 CST 2020, time=2020-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=812034, encodeId=9d3f81203469, content=受教了, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/14/8d72952b2c7c88891566fd24b0601585.jpg, createdBy=21712106382, createdName=1861f7af3bm, createdTime=Sat Aug 22 14:43:04 CST 2020, time=2020-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463983, encodeId=f3de146398328, content=<a href='/topic/show?id=e58691932b6' target=_blank style='color:#2F92EE;'>#诺模图#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91932, encryptionId=e58691932b6, topicName=诺模图)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13c36558142, createdName=zhangyxzsh, createdTime=Thu Jun 11 04:22:36 CST 2020, time=2020-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469166, encodeId=cbca146916681, content=<a href='/topic/show?id=211f98250b' target=_blank style='color:#2F92EE;'>#IND#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9825, encryptionId=211f98250b, topicName=IND)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=16377007930, createdName=xiaogang319, createdTime=Thu Jun 11 04:22:36 CST 2020, time=2020-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485978, encodeId=994a14859e87c, content=<a href='/topic/show?id=2c62100911a3' target=_blank style='color:#2F92EE;'>#风险预测#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100911, encryptionId=2c62100911a3, topicName=风险预测)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e31a8064712, createdName=12498ebem21暂无昵称, createdTime=Thu Jun 11 04:22:36 CST 2020, time=2020-06-11, status=1, ipAttribution=)]
    2020-06-11 xiaogang319
  5. [GetPortalCommentsPageByObjectIdResponse(id=2047266, encodeId=4c61204e2666b, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Fri Jun 19 21:22:36 CST 2020, time=2020-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=812034, encodeId=9d3f81203469, content=受教了, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/14/8d72952b2c7c88891566fd24b0601585.jpg, createdBy=21712106382, createdName=1861f7af3bm, createdTime=Sat Aug 22 14:43:04 CST 2020, time=2020-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463983, encodeId=f3de146398328, content=<a href='/topic/show?id=e58691932b6' target=_blank style='color:#2F92EE;'>#诺模图#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91932, encryptionId=e58691932b6, topicName=诺模图)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13c36558142, createdName=zhangyxzsh, createdTime=Thu Jun 11 04:22:36 CST 2020, time=2020-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469166, encodeId=cbca146916681, content=<a href='/topic/show?id=211f98250b' target=_blank style='color:#2F92EE;'>#IND#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9825, encryptionId=211f98250b, topicName=IND)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=16377007930, createdName=xiaogang319, createdTime=Thu Jun 11 04:22:36 CST 2020, time=2020-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485978, encodeId=994a14859e87c, content=<a href='/topic/show?id=2c62100911a3' target=_blank style='color:#2F92EE;'>#风险预测#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100911, encryptionId=2c62100911a3, topicName=风险预测)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e31a8064712, createdName=12498ebem21暂无昵称, createdTime=Thu Jun 11 04:22:36 CST 2020, time=2020-06-11, status=1, ipAttribution=)]

相关资讯

Int Forum Allergy Rhinol:慢性鼻炎中鼻后神经冷冻消融术后鼻漏预测因子研究

鼻后神经(PNN)冷冻消融在改善过敏性和非过敏性(NAR)引起的鼻漏方面很有前景。早期的案例表明能够改善75%-80%的患者症状,但是预测PNN冷冻消融成功的预测因子还未有研究。最近,有研究人员评估了

盘点:过敏性鼻炎与治疗

【1】Front Pharmacol:大籽蒿花粉过敏性鼻炎1年皮下免疫治疗临床效果评估

Int J Mol Sci :花粉蛋白酶再过敏性障碍中具有多重作用

过敏性疾病是世界范围内的一种重要的健康问题。花粉是过敏性鼻炎,结膜炎和哮喘的主要激发因子。花粉中释放的蛋白酶可能在典型的免疫和炎症响应中具有重要作用。

Int Arch Allergy Immunol:过敏性鼻炎中牛磺酸的体内外抗过敏作用

目前过敏性鼻炎(AR)的治疗并不完善。最近,有研究人员调查了牛磺酸对AR的治疗作用,并鉴定了潜在的机制。

Eur Arch Otorhinolaryngol:慢性咳嗽与上呼吸道咳嗽综合症有关

上呼吸道咳嗽综合症(UACS)也被称为慢性咳嗽(CC),与过敏性鼻炎(AR)、非过敏性鼻炎或者慢性鼻窦炎(CRS)相关,是CC的主要诱因。最近有研究人员对一个UACS患者群体进行了分析,并特别关注了A

Clin Exp Otorhinolaryngol:屋尘螨诱导的过敏性鼻炎小鼠模型中的株系差异

关于粉尘螨(Der f1)诱导的过敏性鼻炎小鼠模型之间的株系差异信息很少。最近,有研究人员比较了2个小鼠株系的差异,并确定了过敏性鼻炎小鼠模型建立的最优Der f1剂量。

Baidu
map
Baidu
map
Baidu
map